Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2025)

Historic EBT Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' EBT Margin rose 359600.0% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.88%, marking a year-over-year increase of 291500.0%. This contributed to the annual value of 28.12% for FY2024, which is 106200.0% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' EBT Margin stood at 0.83%, which was up 359600.0% from 2.7% recorded in Q2 2025.
  • Xeris Biopharma Holdings' EBT Margin's 5-year high stood at 0.83% during Q3 2025, with a 5-year trough of 308.95% in Q2 2021.
  • In the last 5 years, Xeris Biopharma Holdings' EBT Margin had a median value of 45.95% in 2024 and averaged 88.29%.
  • In the last 5 years, Xeris Biopharma Holdings' EBT Margin plummeted by -650200bps in 2021 and then surged by 2041400bps in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' EBT Margin (Quarter) stood at 237.02% in 2021, then soared by 83bps to 40.03% in 2022, then grew by 23bps to 30.7% in 2023, then soared by 72bps to 8.51% in 2024, then surged by 110bps to 0.83% in 2025.
  • Its EBT Margin was 0.83% in Q3 2025, compared to 2.7% in Q2 2025 and 15.34% in Q1 2025.